The company's first product is for the removal of benign growths from the breast. The product obtained US Food and Drug Administration approval last year, and it is also approved for sale in Europe.
Among IceCure's shareholders are Giza (33%), Docor (16%), and Ofer Hi-Tech (11%.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments